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 Mycoplasma gallisepticum, the highly transmissible avian pathogen, is the primary 
etiologic agent of chronic respiratory disease (CRD), a disease largely affecting the respiratory 
tract of poultry, and causing significant economic losses world-wide. Proteins of the variable 
lipoprotein and hemagglutinin (vlhA) gene family are thought to be important for M. 
gallisepticum host interaction, pathogenesis and immune evasion, but the exact role and overall 
mechanisms of phase-variation are not well understood. To better understand the phase variation 
of M. gallisepticum vlhA genes, we have conducted a large scale, next generation sequencing 
analysis of M. gallisepticum sampled directly from the tracheal mucosa of experimentally 
infected chickens as well as those recovered and passaged in-vitro. 
    In the first study, M. gallisepticum was recovered from the tracheal mucosa daily over 
the course of a seven day infection. Of note, the data indicated that, at given time points, specific 
vlhA genes were similarly dominant in multiple independent hosts, suggesting a non-stochastic 
temporal progression of dominant vlhA expression. Additionally we found that vlhA expression 
was not dependent on the presence of exactly 12 GAA repeats, suggesting a previously 
unrecognized mechanism may be responsible, at least in part, for vlhA expression. 
 In the second study, we report that the vlhA profile of M. gallisepticum recovered from 
the trachea of experimentally infected chickens when the input culture expressed an alternate 
dominant vlhA, vlhA 2.02. Here we report that even when the culture is dominantly expressing 
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vlhA 2.02, there is an immediate shift as early as one day post infection to the dominant 
expression of vlhA 3.03, suggesting the expression of this gene many be essential in the earliest 
stages of the infection process.   
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CHAPTER 1: Literature Review 
 
Section 1: General Features 
 
Introduction 
 Mycoplasmas are very small selfreplicating Prokaryotes that lack a cell well. They 
range in genomic size from 580 Kb as seen in M. genetalium (1) to 1,380 Kb as seen in M. 
mycoides subs mycoides LC (2) and have very low genomic G+C content (23-40%)(3). They 
are believed to have evolved from a low G+C containing Gram-positive bacteria through 
degenerative evolution (4, 5).Mycoplasmas  also have very limited biosynthetic capabilities, 
lacking the ability to synthesize many essential molecules, including purines and 
pyrimidines.  and hence must rely on close interactions with host cells for essential nutrients 
and molecules such as amino acids, nucleotides, and fatty acids. Unique to the mycoplasmas 
is the necessity to acquire sterols from host cells to maintain cell membrane integrity without 
the support of a rigid cell wall (2). Mycoplasmas uncharacteristically use the traditional stop 
codon, UGA to encode the amino acid tryptophan (6, 7). These organisms tend to have a 
unusually high mutation rates, likely due to inadequate proof-reading by DNA polymerase 
enzymes (5).  
 Mycoplasmas are common pathogens and tend to exhibit strict host specificity over a 
wide variety of species including humans, animals, reptiles, insects and even plants. They 
can cause a wide range of diseases, effecting respiratory and reproductive tracts, among other 
organ systems. Several mycoplasma species exist however, as commensals, living with their 
host species as part of their natural flora. Very few mycoplasma species cause mortality, but 
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many are associated with morbidity and have significant economic impacts around the world 
resulting from their pathological effects on humans, pets, livestock, and poultry.   
 
History  
 The first mycoplasma was identified by Nocard and Roux in 1898 (8). A semi-
permeable nitrocellulose pouch containing sterile peptone broth was inoculated with 
infectious exudates from a cow exhibiting signs of bovine pleuropneumonia, including 
distention of the interlobular connective tissue by a large amount of clear-yellowish 
albuminous serous fluid. This pouch was surgically placed into the peritoneal cavity of a 
rabbit, along with an uninoculated control and a heat-inactivated control. Approximately 3 
weeks later, the broth containing the infectious exudates became opalescent, while the 
controls remained clear. Eventually, Nocard and Roux were able to cultivate this organism 
axenically in peptone broth supplemented with serum and experimentally inoculate cattle. 
When this organism caused disease in experimentally infected cattle, it was deemed the 
etiologic agent of bovine pleuropneumonia and was therefore named, the pleuropneumonia 
virus (8). After this initial discovery, much taxonomic contention and confusion would ensue 
in the years to follow.  
 Initially this organism was incorrectly classified as a virus. This was the case because 
the organism was able to pass through a filter, which does not allow the typical bacteria to 
pass and invisible by light microscopy (9). Additional evidence supporting this theory came 
when Eaton et. al. (10) isolated, what he termed Eaton’s agent, which would later come to be 
known as Mycoplasma pneumoniae, and it appeared to be unaffected by antibiotics. We now 
3 
 
know the antibiotics used (β-lactam) work by disrupting the cell wall formation, a process 
that mycoplasma species do not undergo, as they lack a cell-wall altogether.  
 In 1910, Borrel et. al. cultured the organism isolated by Nocard and Roux, that was 
thought to be a virus at the time, and saw radiating filamentous structures and therefore 
renamed the organism Asterococcus mycoides (11). In retrospect, these structures that were 
observed were likely due to contamination (9). Just one year later, Martzinovski et. al. 
cultured the same organism and did not see the filamentous structures, but rather diplococcic 
and streptococci, and therefore renamed the organism for the third time, Coccobacillus 
mycoides (12). Several years later, it was incorrectly characterized as an L-form, or wall-less 
form, of other known bacteria, such as the Streptococci due to their similar morphology (13, 
14). 
 By 1935, this group of organisms had undergone seven different name changes. It 
was at this time that Klienberger introduced the term ‘pleuropneumonia-like organisms’ 
(PPLO) to describe these ‘wall-less variants’ of known bacteria (9). It was not until nearly 50 
years after the discovery when the Judicial Commission of the International Committee on 
Bacteriological Nomenclature in 1958 would rule that the name of the etiologic agent of 
bovine pleuropneumonia was Mycoplasma mycoides. It was ten years after that, that the 
committee agreed on the class Mollicutes to describe organisms with ‘the absence of a true 
cell wall and plasticity of the outer membrane’(9).     
 
Nomenclature  
After many years of contention surrounding the taxonomic classification of these 
bacteria, the current classification system places the mycoplasmas in the phylum Tenericutes 
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which are phyogenically related to the Firmicutes phylum consisting of low G+C content 
bacteria such as Bacillus species (2). The only class within the Tenericutes phylum is the 
Mollicutes class, which consists of bacteria that lack a cell wall, have an unusually small 
genome, and have low G+C genomic content. Mycoplasmas belong to the order 
Mycoplasmatales which are known to colonize vertebrates. The Mollicutes in the remaining 
four orders including the Entomoplasmatales, Acholeplasmatales, Anaeroplasmatales, and 
Haloplasmatales, typically tend to colonize insects and plants. Mycoplasmas are classified 
within Mycoplasmataceae, the only family found within the Mycoplasmatales order. The 
Mycoplasmataceae family is further separated into two genera, the Mycoplasmas and the 
Ureaplasmas which are categorized based to their ability to hydrolyze urea as an energy 
source (15).    
 
Minimal Genome Concept  
 Since M. genitalium harbors the smallest genome for any known self replicating cell 
in nature (16), the J. Craig Venter Institute (JCVI) has set out to understand and identify the 
minimal complete set of genes that are necessary for growth in a lab setting, using the M. 
genetallium genome as their foundation. In 2008 JCVI constructed an organism with a 
synthetically created genome based on that of M. genitalium containing what was thought to 
be the minimal complement of genes for a free living cell (17). This organism, M. genitalium 
JCVI-1.0 contained only 582,970 base pairs.  
 To further understand the components that are essential to a free living organism, 
JCVI constructed a synthetic bacterium based on the genome of M. mycoides (18), the largest 
mycoplasma genome containing 1,380 Kb (2). This synthetic organism, JCVI-syn1.0 
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contained 1,079 Kb, and contained all the expected phenotypic properties, including 
continuous self-replication (18).  
 Recently, the researchers at JCVI have further defined the minimal complement of 
genes required for a free living cell by minimizing the JCVI-syn1.0 through a series of cycles 
of design, synthesis, and testing. They were able to reduce the JCVI-syn1.0 from 1,079 Kbs 
to 531 Kbs, creating JCVI-syn3.0, an organism with a genome smaller than any known self 
replicating organism. JVCI-syn3.0 contains only 473 genes and has an approximate doubling 
time of 180 minutes (19).  
 This work, conducted by JCVI, has begun to define the genes that are essential for a 
free living, self-replicating organism using known mycoplasma genomes as their foundation. 
Further investigations into these minimal organisms will shed more light on the functions of 
previously unknown mycoplasma genes and the essential components of free living, self-
replicating organisms.      
 
Section 2: Infectious Mycoplasma species 
 
Mycoplasmas of Humans 
 Several Mycoplasma species are able to infect humans including Mycoplasma 
pneumoniae, Mycoplasma genitalium, Mycoplasma hominis, and Mycoplasma penetrans. 
One of the most studied pathogens in this genus is M. pneumoniae, which causes community-
acquired interstitial pneumonia, commonly referred to as walking or atypical pneumonia (20) 
and is the predominant cause of pneumonia in school aged children, making this disease a 
significant burden to public health (20, 21). Additionally, albeit rare, M. pneumoniae 
6 
 
infections has been reported to lead to other complications such as encephalitis (22, 23) and 
pericarditis (24, 25). There is a close association of M. pneumoniae infection and acute 
asthma and Chronic Obstructive Pulmonary Disease (COPD) due to the strong Th2 response 
elicited by infection with this pathogen (26–28). Aside from the known pathologies of the 
respiratory tract, infection with M. pneumoniae has been linked to renal and gastrointestinal 
complications and hemolytic anemia (21). M. pneumoniae is one of only a few species of 
Mycoplasma that are known to produce a toxin. The M. pneumoniae gene, MPN_372, 
encodes the CARDS (Community-Acquired Respiratory Distress Syndrome) toxin, a ADP-
ribosylating and vacuolating cytotoxin (29) that has been shown to bind human surfactant 
protein A and induce allergic-type inflammation in the airway (30).  
 Cytadherence is a critical initial step in the infection process, as it prevents clearance 
by the host. M. pneumoniae  display a flask shape appearance with a complex tip structure, 
which is described as a slender protrusion from the cell body with an electron dense core(31). 
The cytadhesion molecules must be localized to the tip structure to allow for successful 
attachment of the organism to host cells. Several proteins are found in the tip structure and 
are essential for full functionality of M. pneumoniae attachment including the primary 
cytadhesion P1, proteins B and C, P30 and HMW1, 2, and 3 (32). 
 The tip structure of M. genitalium has been described as very similar to that of M. 
pneumoniae with MgPa (homologous to M. pneumoniae P1), the primary cytadhesion 
molecule localized to the tip structure (3). M. gallisepticum has a similar tip structure where 
the primary cytadhesion, GapA (and homolog to M. pneumoniae P1) and CrmA are essential 
for attachment.  Pre-incubation of  M. gallisepticum  with Fab fragments reactive to GapA 
inhibited attachment of M. gallisepticum to lung fibroblasts, indicating that it is largely 
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responsible for cytadherence (33). In addition, an attenuated strain R (Rhigh) lacking both 
GapA and CrmA demonstrates a significant reduction in attachment (34). Interestingly, 
complementation of Rhigh with gapA did not restore cytadherence, but complementation of 
with both gapA and crmA resulted in the restoration of cytadherence to the level of virulent 
strain R, indicating that these two proteins collaborate in the process of cytadherence (34).  
 It has been reported that when mice are vaccinated with an avirulent M. pneumoniae 
P30 cytadhesion mutant, subsequent challenge with a virulent strain surprisingly results in 
exacerbated disease than unvaccinated control mice (35). This is not the only report of 
vaccine induced disease exacerbation in experimentally infected rodents (36, 37). These 
unsuccessful vaccination studies highlight the need to better understand the basic 
mechanisms and pathogenesis in order to develop effective therapeutics and vaccines.  
 Mycoplasma genitalium, another well studied human pathogen, is associated 
urogenital complications in both males and females, commonly causing sexually transmitted 
non-chlamydial non-gonococcal urethritis in men and pelvic inflammatory disease in women 
(38–40). M. genitalium infections occur globally and, while prevalence rates vary by country 
and community, human infection has been detected in every country where it has been 
sought (41). Unfortunately, the exact mechanism and relationship of M. genitalium and 
human disease is still poorly understood. In addition, there is not a single uniform method for 
clinical detection of infection, creating a large gap in the understanding of how this pathogen 
truly impacts human health. Despite the availability of several qPCR detection kits, none are 
FDA approved for clinical/diagnostic use. Additionally, doxycycline, the typical first line 
antibiotic for urethritis, is not effective against this pathogen, and resistance to macrolides 
has recently been reported (41) emphasizing the need to further understand the pathogenesis 
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of this emerging pathogen. Recent technological advances, namely the Nucleic Acid 
Amplification Test (NAAT) allowing for  rapid and accurate detection, has begun to allow 
scientists to perform more studies to start to elucidate the pathogenic mechanism employed 
by this emerging sexually transmitted infection (41).  
 Another infectious Mycoplasma species that is able to colonize the human urogenital 
tract is M. penetrans (38). This pathogen was the first identified invasive member of the 
Mycoplasma genus and has been reported to penetrate Eukaryotic cell membranes using its 
tip structure (42). A correlation  was established between M. penetrans and HIV infection 
where the rate of M. penetrans infection was significantly higher in patients with HIV, 
suggesting they are potential co-pathogens (42). However, subsequent studies have reported 
that there is no distinct pathology associated with this infection and no compelling evidence 
to suggest that they act do as co-pathogens (43). Host immune evasion is believed to be 
achieved in this organism though the phase variation of the Mpl lipoproteins (44, 45), 
aggulutination of red blood cells, lymphocytes and monocytes (42) and it has been 
demonstrated that M. penetrans can bind IgA, serving as a defense mechanism evading 
clearance by IgA specific antibodies (46).  
 M. hominis, another human pathogen that can inhabit the urogenital tract, is 
associated with bacterial vaginosis and have been linked to pre-term births (38). M. hominis 
induces the production of inflammatory cytokines and chemokines that are thought to be 
responsible for pre-term births and potential brain damage commonly observed in infections 
(47–49). A recently identified gene, goiC, appears to be associated with virulence, 
specifically related to the bacterial density in the amniotic fluid and pre-term births as 
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isolated mutant strains lacking this gene, show a significant decrease in bacterial density in 
the amniotic fluid and reduction in pre-term births (50).  
 Taken together, these data demonstrate the lack of complete understanding of the 
pathogenic mechanisms employed by these mycoplasma species that infect humans and 
highlight the need for a more complete understanding of these organisms and their virulence 
factors.   
 
Mycoplasma of Porcines  
 Two main Mycoplasma species are known to infect swine and cause significant 
economic losses to farmers around the world. M. hyopneumoniae is the causative agent of 
porcine enzootic pneumonia, a highly contagious and infectious disease of swine M. 
hyopneumoniae can contribute to the super infection known as the porcine respiratory disease 
complex (51) . Recent genomic comparisons of a pathogenic strain with a high-passage 
attenuated strain identified genes and gene families that are important in the virulence of the 
organism, including cytadhesins, cell envelope proteins (P95), cell surface antigens (P36), 
chaperone proteins (DnaK), and genes involved in metabolism (52). A significant portion of 
the pathogenesis can be attributed to the ability to attach to swine respiratory cells via the 
P97 cytadhesion (53) and to bind host glycosaminoglycan heparin sulfate (54, 55).  
 M. hyorhinis, spread by respiratory secretions, can cause serofibrinous to 
fibrinopurlent polyserositis and arthritis in swine (56). Of note P37, a surface exposed 
lipoprotein that binds pyrophosphate (57) has been shown to induce tumor transformation of 
Eukaryotic cells (58–60). It has recently been reported that the P37 lipoprotein can transform 
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normal gastric cells to cancer cell though activation of the PI3-kinase-AKT signaling 
pathway, initially stimulated though the epidermal growth factor receptor (EGFR) (61).  
 
Mycoplasmas of Bovines  
 The Select Agent, Mycoplasma mycoides subs. mycoides Small Colony (MMMSC) 
was the first Mycoplasma described by Nocard and Roux in 1898 (62) and is a highly 
contagious respiratory pathogen of cattle that can cause fatal pleuropneumonia (63). This 
organism is one of the few species of mycoplasma that causes mortality. MMMSC has been 
described as the single most important threat to the cattle industry in Africa and economically 
the most important mycoplasmal pathogen in the world (3). The United States has been free 
of this pathogen since 1893 (64), however re-emergences of this pathogen has been reported 
in Europe as recently as that late 19th century with confirmed cases in Portugal and Italy and 
sporadic outbreaks in France and Spain (3). Currently, there are commercially available live 
attenuated vaccines, however they provide inadequate protection, require annual boosting, 
and can revert to virulence, demonstrating the need for improved vaccines (65). It has been 
speculated that MMMSC can evade the host immune system via the phase variable Vmm 
lipoproteins, a trait shared with many other mycoplasma species (66). Of interest and related 
to the virulence of MMMSC, is the ability to ferment glycerol via the glpO gene (67) 
resulting in the production of hydrogen peroxide (68, 69) a reactive oxygen species, that is 
known to cause cellular damage to host Eukaryotic cells.  
 M. bovis, another mycoplasma pathogen of cattle, has been reported to cause mastitis, 
(70) pneumonia, (71, 72) and contributes to Bovine Respiratory Disease Complex (73) which 
can lead to broncopneumonia. M. bovis has been reported to evade host immune responses 
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though the phase and antigenic variation of the surface exposed vsp genes. Of significance is 
the membrane associated polysaccharide is an inflammatory toxin that causes mastitis in 
cattle when inoculated into the udder (74).  
 
Mycoplasmas of Caprines  
 M. capricolum subs. capripneumoniae, formally known as the F-38 group of 
mycoplasma, is a significant pathogen of goats and the causative agent of Contagious caprine 
pleuropneumonia a frequently fatal disease. It has also been reported to cause mastitis and 
arthritis (75). This Select Agent is particularly a problem in Africa and Asia, causing 
devastating economic losses (3). Little is  understood about the pathogenesis and virulence 
mechanisms of this organism, but genomic comparisons of the highly virulent and frequently 
fatal M. capricolum subs. capripneumoniae and M. capricolum subs capricolum show that 
the lppA lipoprotein gene is truncated in M. capricolum subs. capricolum, suggesting it may 
be involved in the virulence and pathogenesis (76).       
 M. agalactiae causes mastitis resulting in the marked decrease of milk production in 
small ruminants, causing a significant economic impact (77). The organism is often isolated 
from milk samples of infected animals and can be a significant contaminat in milk storage 
tanks (78). M. agalactiae can be vertically transmitted from doe to kid through direct contact, 
during suckling (77). Virulence determinants of this pathogen includ biofilm formation (79), 
hydrogen peroxide production (80), anda  putative cystine desulfurase, nifS  which is 
essential for growth inEukaryotic co-culture (81).  
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Mycoplasmas of Rodents  
 M. pulmonis, a respiratory pathogen of mice causes a disease similar to atypical 
pneumonia in humans, and can induce allergic airway disease and airway hyper-reactivity 
(82), making this organism an excellent model to study the role of both the innate and the 
adaptive immune response in the respiratory tract (3). Virulence of this organism is related to 
immune evasion via phase variation of the vsa variable lipoproteins (83), which also have 
been report to be associated with  biofilm formation(84). Additionally, M. pulmonis produces 
a hemolysin, nuclease, and a glycoprotease which is of particular interest, as hydrogen 
peroxide production has been linked to virulence in other mycoplasma species (85).  
 M. arthritidis has been linked to polyarthitis in rats and chronic proliferative arthritis 
in mice, but has also been reported to have been isolated from animals without arthritis (3, 
86). M. arthritidis hydrolyzes arginine to produce energy (86) and contains multiple variable 
lipoproteins speculated to be involved in immune evasion (87). Of particular interest, is the 
superantigen, M. arthritidis T-cell Mitogen (MAM) (88) which acts by binding the alpha 
chain of the MHC II molecule on B cells and the variable Beta chains on T helpers cells, 
thereby connecting them (89–91). This linkage results in lymphocyte activation in an antigen 
independent fashion leading to the uncontrolled production of inflammatory cytokines and 
polyclonal antibodies (92, 93).  
 
Mycoplasmas of Felines  
 M. felis was originally isolated from a cat with severe conjunctivitis (94) and has seen 
been linked with pneumonia (95). Interestingly, it has also been reported to cause pleuritis 
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(96)  and lower respiratory tract diseases in horses (97). M. gateae has been reported to cause 
erosive polyarthritis and synovitis in felines (98, 99).  
 
Mycoplasma of Canines   
 There have been 15 species of mycoplasma isolated from or detected in dogs, (100) 
however their roles in respiratory infections is not well understood. They are thought to be 
part of the normal flora of the upper respiratory tract but have been observed colonizing the 
lower respiratory tract during infections such as pneumonia (101). M. edwardii and M. 
spumans have been associated with respiratory diseases in dogs.  M. cynos has been reported 
to cause respiratory disease in young dogs and has been associated with canine infectious 
respiratory disease (CIRD) (100) and M. canis causes urinary tract infections and can lead to 
infertility (102). These two pathogens in addition to M. molare, secrete sialidase, a feature 
unique to these species in the genera, as other mycoplasma species have membrane bound 
sialidase (103). Sialidase has been associated with virulence in other species, such as M. 
gallisepticum, where a transposon insertion mutation in the sialidase gene demonstrated 
reduced lesions and recovery in experimentally infected animals (104). Sialidase has also 
been associated with virulence in M. synoviae where it was reported that those strains 
demonstrating higher virulence exhibited significantly higher levels of sialidase activity 
suggesting an enzymatic basis for virulence (105).  However, to date, the role of secreted 
sialidase in the virulence of these canine pathogens still remains unknown.  
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Mycoplasmas of Reptiles and Piscines  
 In 1995, an epidemic of acute multisystemic inflammatory disease was discovered in 
captive alligators in Florida. Four years later it was confirmed that the etiologic agent was the 
flesh-eating bacterium, M. alligatoris (106). Infection results in interstitial or fibronecrotic 
pneumonia with fibrinous polyserositis and multifocal arthritis (107). Identified potential 
virulence factors in this organism include hyaluronidase and sialidase which have been 
shown to induce the CD-95 signaling pathway, resulting in apoptosis of Eukaryotic cells 
(108).  
 The closely related M. crocodyli (98% 16s rRNA similarity) shows a comparaitivly 
reduced virulence in crocodiles, which could be due, at least in part, to the lack of sialidase 
(109). It has been reported that while M. alligatoris contains both hyaluronidase and 
sialidase, genome comparisons suggest that M. crocodyli contains only hyaluronidase and 
lacks sialidase (109). This further emphasizes the link between the enzymatic activity of 
sialidase in mycoplasmas and virulence. Another mycoplasma pathogen of reptiles, M. 
agassizii, emerged during the late 1900’s causing rhinitis with palpebral edema and serous 
nasal and ocular discharge in the desert tortoise (110, 111). 
 The only known mycoplasma species to infect fish, M. mobile, can cause severe 
necrosis of the gills of infected fish (112, 113). Interestingly, this species is the fastest motile 
mycoplasma and is considered to be the model organism for gliding motility in which M. 
mobile, and other motile mycoplasma species, are able to glide on solid surfaces without 
containing any flagella, pili, or gene homologs to any known motility systems. M. mobile is 
able to move by gliding motility and is explained though a model termed the ‘centipede 
model’ (114). During motility, the tip structure protein Gil349 attaches to sialic acid residues 
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on host cells and ATP is hydrolyzed, providing the necessary energy. This causes a 
conformational change, which physically moves the mycoplasma forward. The next sialic 
acid is released and the process is repeated (114).     
 
Mycoplasmas of Avians 
 M. synoviae has been implicated in infectious synovitis, respiratory lesions, and 
airsacculitis in poultry (115). Virulence determinants likely include immune evasion via the 
phase variable vlhA lipoproteins (116) and sialidase activity (104). However, reliable 
methods for specific gene mutations have not yet been developed for M. synoviae, making it 
difficult to directly assess how a specific gene is related to the virulence of the organism. 
Despite these potential virulence factors, the disease is well controlled in poultry with the use 
of a live attenuated vaccine (117–119).  
 M. iowae has been reported to cause airsacculitis, embryo mortality, and physical 
abnormalities in infected poultry (115). It is resistant to bile salts (120) and commonly 
isolated from the digestive tract of infected embryos (121). Interestingly, M. iowae is able to 
both ferment glucose and hydrolyze arginine, two processes that are usually not seen together 
in an individual mycoplasma species (122).    
 Several other avian mycoplasma species have been identified including M. 
gallinarium, which has been reported to cause mild respiratory signs in geese when 
concurrently infected with parvovirus, M. columbinasale which causes rhinitis and 
pharyngitis in pigeons, and M. anseris which has been reported to cause lesions in geese in 
conjunction with M. cloacale. Additionally M. meleagridis has been reported to cause 
sinusitis, airsacculitis, and infection of the genital tract of turkeys (123). 
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Spiroplasmas and Phytoplasmas  
 Spiroplasmas and Phytoplasmas, belonging to the class Mollicutes, are mostly plant 
pathogens that have a dual host life cycle dependent on sap-feeding insects for transmission 
between plant hosts. The sap-feeding insect vectors, including planthoppers, leafhoppers, and 
psyllids, acquire the bacterium by ingesting the phloem of infected plants (124). Upon 
ingestion, the bacteria reach the mid-gut lumen and must traverse the gut epithelial cell layer, 
by aligning the tip structure between the microvilli, to reach the circulatory system. To be 
transmitted to the new plant host, the organism must reach the salivary glands and become 
incorporated into the salivary secretions of the insect host (124). Little is understood about 
the molecular mechanisms of pathogenesis in these plants pathogens as they are un-cultivable 
in axenic media, but it has been demonstrated that this dual host lifestyle requires the 
organism to successfully pass many physical barriers and requires several specific protein-
protein interactions between the bacterium and insect host.  
 These pathogens can infect a wide range of plants (3, 124–126) causing a significant 
economic impact around the world and have been linked to horseradish brittle root disease, 
citrus stubborn disease, and grass stunt disease among others (125, 127, 128). The Aster 
Yellows phytoplasma strain Witches’ Broom infection leads to phyllody (conversion of 
flowers to leaf-life structures), virescence (greening of floral organs), and Witches’ Broom 
(increased proliferation of stems). These changes are particularly beneficial for the bacteria, 
as they make the plants more attractive to the insect vectors, enhancing the spread of the 
bacteria (124, 126, 128). While little is understood about the pathogenic mechanisms of these 
organisms, it has been reported that the Aster Yellows phytoplasma strain Witches’ Broom is 
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able to release effector proteins inside the phloem of the plant, including the recently 
identified Sap54, which has been linked to the observed pathologies. This novel virulence 
factor functions by inhibiting floral development by promoting the degradation of the plant 
MADS transcriptions factors which have an essential role in flower development (124).  
 
 
Section 3: Mycoplasma gallisepticum 
 
Disease and Significance  
 Mycoplasma gallisepticum is largely a respiratory and reproductive pathogen of 
poultry. Infection with virulent strains, such a strain Rlow, lead to clinical manifestations 
including tracheal lesions, airsacculitis, inflammation, metaplasia, loss of cilia, and 
thickening of the tracheal mucosa (129).  Early lesions are typically composed of heterophils 
and macrophages, while later lesions contain large numbers of lymphocytes with high 
proportions of T-cells (130). The clinical impacts of this include coughing, sneezing, 
respiratory rales, and nasal and ocular discharge (131) .  If this pathogen is not cleared by the 
host, it can cause a chronic disease state (2). 
 M. gallisepticum contributes to Chronic Respiratory Disease (CRD), a polymicrobial 
syndrome largely effecting the respiratory tract, yet also affecting other organ systems, such 
the reproductive tract (132, 133). Concurrent infectious with Avian Influenza virus (AIV) 
(134), Newcastle disease virus, infectious bronchitis virus (135), pathogenic E. coli, 
Haemophilius , and avian rhinotracheitis virus (136) have been reported to enhance clinical 
signs associated with CRD. The exact sequence and pathogenesis of co-infecting organisms 
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and CRD is poorly understood at this time. However,  Sid et al., recently reported that co-
infection with M. gallisepticum and AIV promoted bacterial growth, inhibited antiviral gene 
expression and affected AIV attachment to the host cell by desialylation of α-2,3 linked sialic 
acids (134), beginning to elucidate the biological mechanisms involved in co-infection.  
 M. gallisepticum is transmitted throughout the flock via horizontal transmission from 
inhalation of respiratory droplets from infected birds or through conjunctival exposure (136, 
137). Additionally, M. gallisepticum can spread via vertical transmission from the layer to 
the egg (138).   
 Infection does not usually result in mortality, especially in older chickens, but the 
morbidity has significant adverse effects to poultry industries around the world due to the 
necessity to cull positive flocks and condemn and downgrade carcasses, decreased egg 
production and hatchability, decreased egg quality, and a substantial reduction in weight gain 
(139, 140). The economic losses to the poultry industry are substantial as it is estimated to be 
$588 million per year lost in broiler industries alone in the United States with an additional 
$132 million lost from the egg laying industry (115, 141, 142).  
 Because of this and other significant poultry diseases, the United States Federal 
Government implemented the National Poultry Improvement Plan (NPIP) in the 1960’s, a 
collaboration between both state and federal departments of agriculture to use new 
technology to improve poultry and poultry products throughout the United States by 
establishing guidelines for control of M. gallisepticum (and other significant poultry 
pathogens such as M. synoviae, Salmonella, and avian influenza) in primary breeder flocks 
(143). Because of the severe economic impact, rapid spread, and chronicity of this infection, 
M. gallisepticum was determined to be one of the top 3 most significant avian pathogens to 
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U. S. poultry producers at the USDA ARS/CSREES National Animal Health Program 
Planning Workshop (144).  
 The current strategies employed by commercial farms include strict biosecurity 
measures, antibiotic therapy, and vaccination programs to attempt to prevent and/or control 
disease. However, medications cannot effectively be used to eliminate infection from an 
entire flock and therefore is not an adequate long-term solution. In severe cases, culling of M. 
gallisepticum positive flock is also used to control infection and spread of this important 
disease (145). 
 M. gallisepticum has been shown to cause significant pathology in other species 
causing infectious sinusitis in turkeys and conjunctivitis in house finches (2, 146) which 
could promote the spreading, especially between back-yard flocks. Biosecurity measures 
have been put in place on many farms to prevent  such spread (147). Of particular interest is 
the emergence of a new strain of M. gallisepticum that was identified in house finch 
(Carpodacus mexicanus) populations in the eastern United States in 1994 (146). M. 
gallisepticum has also been isolated from many other species of passerine birds such as 
purple finches, blue jays, and American goldfinches (148–150).  This M. gallisepticum strain 
was shown to be genotypically different from the poultry strains by Random Amplification 
of Polymorphic DNA (RAPD) and Amplified-fragment length polymorphism (AFLP) 
analysis (151) and caused severe conjunctivitis in the house finches (149). Interestingly, only 
minimal to mild disease was displayed when these house finch M. gallisepticum strains were 
used to experimentally infect poultry (152). 
 However, over the course of the epizootic event, the house finch-related M. 
gallisepticum strains demonstrated increased virulence in the house finch host, but a 
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significant reduction in virulence in experimentally challenged poultry, indicating possible 
reciprocal evolution of house-finch related M. gallisepticum virulence in house finch and 
poultry hosts (S. Geary, unpublished data). Of note, is a recent study comparing the genomic 
changes in the M. gallisepticum house finch strains between the initial index case in 1994 and 
seven other isolates separated both spatially and temporally (153). The data indicated that the 
most dramatic genomic differences were observed in the phase-variable lipoprotein 
hemagglutinin genes vlhA in both presence and genomic location, suggesting a potentially 
important role of these genes in the virulence of this pathogen (153)    
    
 
Current M. gallisepticum Vaccines  
 Over the years, several attempts have been tried to develop an efficacious and safe 
vaccine to protect poultry from M. gallisepticum infection. To date, two types of 
commercially available vaccines exist, bacterins and live attenuated vaccines. Bacterins, 
which are inactivated suspensions of whole organisms, initially seemed promising in the field 
as vaccinated and challenged birds showed a lack of clinical signs and reduced air sac lesions 
upon gross examinations (154).  Furthermore, it was demonstrated that the use of bacterins as 
vaccines reduced the decline in egg production associated with M. gallisepticum infection 
(154–157) and prevented vertical transmission (158). Unfortunately, later reports showed that 
the reduction in bacterial load was only minimal, at best (159) and microscopic lesions, while 
less severe, were still present (160). Furthermore, the use of bacterins did not protect against 
infection with heterologous M. gallisepticum strains (154–157, 161).  
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 Meanwhile the live attenuated vaccines were being evaluated and compared to the 
bacterins, showing potentially more promising results. The live F strain vaccine derived from 
a naturally attenuated strain, was first identified in 1956 (162). Since it was first identified, 
several safety and efficacy studies have been conducted in both chickens and other poultry. 
In chickens, the live F strain vaccine elicits a strong serological response and, in fact, that 
response is the strongest of any commercially available M. gallisepticum vaccine (163). That 
serum antibody response, however, is not comparable in magnitude to that of a chicken 
challenged with pathogenic M. gallisepticum strain Rlow (164). Vaccination with live F 
strain provides good protection for layers while inducing no lesions (141, 165, 166). This 
vaccine strain is able to displace the virulent R strain from infected flocks (167) which has 
been suggested to a possible mechanism of protection as the F strain out-competes the 
virulent strains in the airway, reducing the bacterial load (168). Of note, the F strain vaccine 
has been demonstrated to be readily differentiated from field strains through the use of 
Western blotting and RAPD fingerprinting (169, 170). Most importantly, vaccination with 
the live F strain prevented the development of lesions and disease in birds when vaccinated 
birds were subsequently experimentally challenged with virulent strain Rlow (139, 171, 172). 
However, the live F strain vaccine was not optimal in all conditions. Vaccination caused 
severe lesions and disease in turkeys and young chickens (173) and demonstrated the ability 
to pass vertically to the egg (174). In addition, vaccination with the live F strain has been 
linked to adverse effects in the reproductive performance in layers, causing a reduction in 
total egg production due to a delay in lay onset (165, 175, 175). Furthermore, transmission to 
naïve poultry has been reported (176) which is of concern to farmers, as chickens and turkeys 
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are often kept in close proximity, creating the possibility of transmission from a vaccinated 
chicken (177).  
 Despite the negative impact the F strain vaccine has on the layers, it has been reported 
that F strain vaccinated birds that have been subsequently challenged with a virulent Rlow 
strain, have a higher and more successful laying rate and display less vertical transmission 
than their unvaccinated counterparts (141, 161). Despite the obvious safety concerns 
surrounding the live F strain vaccine, it still elicits a strong antibody response and provides 
complete protection against challenge, fairing far better than any other commercially 
available vaccine (163). 
 Another live attenuated vaccine, the ts-11, a temperature sensitive mutant has been 
generated though chemical mutagenesis (178). This strain, which is administered via eye  
drop displayed a temperature sensitive phenotype with a maximum growth temperature of 
33°C, well below the body temperature range of the chicken (40.6° to 41.7°C) and is unable 
to permanently colonize the lower respiratory tract. The ts-11 strain is, however, able to 
colonize the upper respiratory tract of the chickens, where the temperature is lower, and 
stimulate a protective immune response. ts-11 has been demonstrated to be safe in both 
chickens and turkeys as it did not cause clinical signs or disease. Minimal lesions were 
observed in less than 10% of animals and egg production remained normal (179–181). 
However, while a safer option, ts-11 does not always provide protection from challenge and 
the level of protection is variable (180, 181). When assessed, it was determined that the 
magnitude of the antibody response was very low, which was likely the key reason for the 
inconsistent protection reported (180, 182, 183). The ts-11 strain has been shown to persist in 
vaccinated animals for several months (179) with limited horizontal transmission (183) and 
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no reported vertical transmission to eggs (184). The egg quality is not adversely effected by 
vaccination (185) and in fact layers demonstrate an increase in egg production when 
vaccinated and subsequently challenged, compared to their unvaccinated counterparts (184). 
While the ts-11 strain is unable to displace the virulent Rlow strain in infected birds, it has 
been reported to be able to displace the F strain (186). Even though the live attenuated, 
temperature sensitive ts-11 vaccine strain may not be able to provide as much protection as 
the live F strain vaccine, it is the safer option, especially for turkeys and young chicks.   
 The final commercially available, live attenuated vaccine is the 6/85 vaccine which 
was generated though serial passage in-vitro (163, 179). This vaccine strain was found to be 
safe in both chickens and turkeys demonstrating the formation of only few mild lesions in a 
small percentage of experimental animals (187) with no effect on egg production or egg 
quality (188). However, the efficacy of the vaccine in birds challenged with a virulent strain 
is variable and weak (187) and elicits minimal to no detectable serum antibody response 
(163). The vaccine strain is unable to prevent the spread of the challenge strain from 
vaccinated animals or displace virulent strains from infected birds (186, 189). More 
concerning is the report of 6/85-like strains being recovered from un-vaccinated animals, 
suggesting the possibility of reversion of this vaccine to virulence (190). However, this 
reversion has not yet been successfully reproduced experimentally (191) and the isolated 
strain was unable to produce disease in experimentally infected animals (190).  
 The availability of efficacious and safe vaccines that can be administered to an entire 
flock of animals is significantly lacking at this point in time. On one side there is the live F 
strain vaccine, which elicits high antibody titers and provides sufficient protection, but is 
virulent in young chickens and turkeys. On the other side, there is the ts-11 and 6/85 vaccine 
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strains which are much safer and cause mild to no adverse effects, but do not provide 
sufficient protection to the flock against virulent M. gallisepticum strains. This demonstrates 
the need for the development of a single efficacious and safe vaccine to protect poultry from 
M. gallisepticum infections.  
 The Center of Excellence for Vaccine Research (CEVR) at Uconn has produced two 
live attenuated vaccine strains to protect chickens from infection. One of the vaccines was 
created by complementing an avirulent strain with a cytadhesin molecule, while the other 
strain was developed by disrupting a known virulence factor in a virulent strain. The first live 
attenuated vaccine was created by complementing the avirulent Rhigh strain with the 
cytadhesin gene gapA. This resulting strain was termed GT5. It was demonstrated that GT5 
was safe at high doses and prevented lesions when vaccinated birds were challenged with 
virulent strain, Rlow. The same study reported increased production of M. gallisepticum 
specific IgG but surprisingly not IgA (192). It was reported that lymphocytes were arranged 
in organized follicles and both M. gallisepticum specific IgA and IgG mucosal plasma cells 
were produced as early as four days post-vaccination (193).  
 Mg7 was the second live attenuated vaccine developed by CEVR. It was created by 
disrupting the metabolic gene lpd via transposon mutatgenesis in the virulent strain, Rlow. 
This vaccine displayed complete attenuation in experimentally infected animals (194). Much 
like GT5, this vaccine strain was safe at high doses and prevented colonization and therefore 
lesion formation when challenged with the virulent Rlow strain. Similarly these vaccinated 
birds produced increased amount of M. gallisepticum specific IgG (168).  
 Unfortunately these live attenuated vaccine strains were created using transposon 
insertions, containing a gentamicin selectable marker, making them unsuitable for 
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commercial production in their current forms. Despite that, both vaccines have passed the 
“proof-of-concept” stage of development and are superior in performance to ts-11, 6/85 and 
the F in laboratory-controlled studies (168). Geary et. al. believe that  the need to develop a 
rationally designed, safe, and efficacious vaccine still exists and that further knowledge of 
the pathogenic mechanisms employed by this organism are necessary to accomplish that 
goal.        
 
 
M. gallisepticum Virulence Factors  
 Adequate understanding regarding the mechanisms of pathogenesis of M. 
gallisepticum are lacking, but significant strides have been made in elucidating the genes and 
pathways related to virulence, especially after the complete genome was sequenced (195) and 
compared to Rhigh, an avirulent high passage mutant (196). There were several genes 
identified as absent in Rhigh, including the major cytadhesin gapA and the gene encoding the 
cytadhesin associated molecule CrmA (196). An essential first step in colonization of any 
pathogen is cyadhesion as it prevents mechanical clearance by the host. Despite some 
differences, GapA and CrmA are homologs of the well characterized P1 and B/C adhesion 
molecules of M. pneumonia (33, 34, 197) . As previously discussed, complementation of 
Rhigh with gapA or crmA alone did not restore cytadherence or virulence of the organism to 
wild-type levels. However, complementing with both gapA and crmA did in fact restore both 
cytadherence and virulence of the organism (34). Additionally, it has been demonstrated that 
transposon insertion mutations in the virulent Rlow gapA and crmA genes abolish the 
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cytaherence capabilities and significantly diminish the virulence of the organism in the 
natural host (198) further linking these two genes to virulence of M. gallisepticum.  
 Two additional genes that were found to be lacking from the avirulent Rhigh strain 
were the genes responsible for fibronectin binding, hlp3 and plpA(196). These products were 
identified when the peptides that exhibited similarity to known fibronectin binding proteins 
were shown to bind the gelatin/heparin-binding domain of fibronectin (199). PlpA 
demonstrated homology to the well-characterized cytadhesin associated protein P65 of M. 
penumoniae (pneumoniae-like protein A) and Hlp3 demonstrated homology to the 
cytoskeletal protein of M. pneumoniae, HMW3 (HMW3-like protein) (199).  
 Virulence has been linked to proteins involved in metabolism in many pathogens (67, 
68). The metabolic protein, dihydrolipoamide dehydrogenase (lpd) is a part of the pyruvate 
dehydrogenase complex pathway, a pathway responsible for the production of ATP during 
glycolysis. When a transposon mutant was generated via an insertion in the lpd gene of M. 
gallisepticum, the organism was completely attenuated and was no longer able to be 
recovered from experimentally infected birds (194). This attenuation was likely the result of 
the inability of the organism to produce sufficient amounts of ATP and therefore energy for 
survival in the host (194).  
 Another metabolism-related gene, malF has been reported to be essential for the 
persistence of M. gallisepticum in experimentally infected birds. When a transposon mutation 
was made in this predicted ABC sugar transport permease gene, the organism was unable to 
be recovered from experimentally infected bird or cause disease, suggesting its necessity for 
persistence (200).   
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 MslA is an immunogenic mycoplasma-specific lipoprotein that exhibits reduced 
expression in the live attenuated F strain vaccine (201). When a transposon mutant disrupting  
mslA was created, the organism showed reduced recovery and attenuated virulence in 
experimentally infected chickens (201). Since homologs of this lipoprotein are only found in 
mycoplasma species, it was coined mycoplasma-specific lipoprotein A (mslA). While its 
relationship to the virulence of M. gallisepticum has been demonstrated, the exact role it 
plays is not yet completely understood. However, it has been hypothesized that MslA binds 
Toll-like receptors (TLRs) which in turn activate NF-κB, leading to the production of 
cytokines and chemokines that result in inflammation (201).  
 The M. gallisepticum gene, MGA_0329, a homolog of sialidase in M. pneumoniae 
has been linked to virulence in M. gallisepticum. A transposon mutant disrupting the gene, 
resulted in loss of sialidase activity and when used to experimentally infect chickens, showed 
significantly less severe tracheal lesions and mucosal thickening in addition to a significant 
reduction in bacterial recovery (104). However, complementation restored wild-type levels of 
sialidase activity, but did not restore the virulence. This was surprising as sialidase 
production has been shown to correlate with virulence in the closely related, M. synoviae 
(105) as strains with increasing levels of sialidase activity showed increased virulence in-vivo 
while those strains with less sialidase activity produced mild to no respiratory lesions in 
chickens (105). It has been hypothesized that since sialylation protects against the hydrolysis 
of glycosidic bonds on the host cell surface and degradation of the host cell extra-cellular 
matrix, removal of these sialic acid residues can expose new host antigens and play a role in 
autoimmune complications of infections (202).  These data suggest that the link between 
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sialidase activity and virulence is more complicated than originally thought in M. 
gallisepticum, and not completely understood at this time.  
 Several mycoplasma species (M. bovis for example) have the ability to ferment 
glycerol and produce hydrogen peroxide, a potent reactive oxygen species known to cause 
cytotoxicity in Eukaryotic cells (67, 68). Surprisingly, when transposon mutants were created 
in the M. gallisepticum glpO, glpK, and glpF genes of the glycerol transport and utilization 
pathway, the organism still retained virulence as evidenced by typical lesions in the tracheas 
of infected chickens,  suggesting glycerol metabolism and hydrogen peroxide production is 
likely not a virulence factor in M. gallisepticum, as previously hypothesized. These data 
demonstrate that the function of this pathway is not yet understood in M. gallisepticum.     
 Potentially tied to the virulence of M. gallisepticum is the phase-variable lipoprotein 
hemagglutinin gene family (vlhA) (153). This gene family, further discussed in detail below, 
has been reported to display significant genomic changes in size and location between strains 
with varying levels of virulence suggesting they may play a role in the virulence of M. 
gallispeticum (153).  
 
  
Section 4: Phase and Antigenic Variation in Mycoplasma 
 
 Mycoplasma species have demonstrated the ability to establish chronic infection in a 
wide range of host species, even when faced with strong immune pressure. This success may 
be due, at least in part, to the ability of these organisms to rapidly change the expression and 
size and even the structure of their surface exposed proteins. These events lead to a dynamic 
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and plastic cell membrane allowing for rapid adaptations to the environment, enabling the 
bacteria to escape host immune pressures and enhance host interactions providing the 
bacteria with optimal chances for survival (203).  
  Phenotypic variation encompasses both phase (the on/off expression of a given 
antigen) and antigenic variations (the expression of alternate forms of a given antigen)(203). 
At least four molecular strategies have been described in mycoplasma species that affect the 
expressed antigens. They include (1) on/off switching via DNA slippage and point mutations, 
(2) surface antigenic variation via DNA rearrangement (site-specific DNA inversions), (3) 
domain shuffling via homologous recombination, and (4) epitope masking and unmasking 
(203).  
  
DNA slippage 
 Among mycoplasmas, the first antigenic variation mechanism described was the vlp 
genes of the procine pathogen, M. hyorhinis. These genes are control by a molecular switch 
involving DNA slippage (slipstrand mutations) in the promoter region (204–206). The vlp 
gene family contains 3-8 genes designated A-G, each representing a single transcription unit 
with a poly-A tract in the promoter region (207, 208). Elongation or contraction of this polyA 
tract by a single nucleotide is sufficient to abolish transcription (206). The change in length 
causes structural alternations in the DNA curvature, no longer presenting an optimal 
conformation for transcription initiation (206). These genes also demonstrate size variation  
through intragenic expansion and contraction of tandem repeat regions, wherein it has been 
reported that variant cells expressing a long vlp appear to be resistant to antibody mediated 
growth inhibition, while the short versions are susceptible (209).  
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 A similar mechanism has been reported for the phase-variable cytadhesin gene, maa2 
in M. arthritidis where the gene is only expressed when it is preceded by exactly 16 thymine 
residues (210). Similarly, phase variation of the vmm gene of M. mycoides subs. mycodies SC 
and the vmc of M. capricolum subs. capricolum are under the control of reversible promoter 
mutations (66, 211). These genes are expressed when the poly-TA tract contains exactly 10 
di-nucleotide TA repeats (66, 211). Additionally, the expression of the vaa gene of M. 
hominisis depends on the insertion/deletion of adenine residues in the poly-A tract, where 
mutations result in the production of an in-frame stop codon and truncated protein (212).  
 M. gallisepticum contains the phase-variable lipoprotein hemagglutinin gene family 
(vlhA, previously referred to as pMGA) which consists of 43 closely related genes distributed 
across 5 loci, totaling just over 10% of the gene in strain Rlow (195). Previous studies 
initially indicated that only one vlhA gene was expressed at any one time, however 
subsequent studies have shown that more than one gene can be expressed simultaneously in a 
population. (213, 214). vlhA expression has been reported to be dependent on the presence of 
exactly 12 GAA tri-nucleotide repeats upstream of the expressed gene and is believed to 
change via slip-stranded mutations in the promoter regions (117, 214–216). It has also been 
hypothesized that vlhA gene expression is stochastic, driven by anti-VlhA mediated negative 
selection and resulting in random outgrowth populations (117). The exact function of the 
VlhAs are still unknown, but has been speculated to involve immune evasion during the 
infection process (217) and variation has been loosely associated with virulence in other M. 
gallisepticum strains (153). Additionally it has been suggested that the ability of the gene 
products to bind red blood cells could be a factor to aid the dissemination of the organism 
thought the infected host (218). Reports have also suggested that VlhAs may function in a 
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weak initial attachment of M. gallisepticum to target host cells.  Despite these data, with 
recent technology a current study, described in detail in chapter 2, suggests that another 
mechanism is, at least in part, responsible for the control of vlhA gene expression (219). 
 
DNA rearrangement  
 Many mycoplasma species can achieve phase variation by DNA inversion via site 
specific recombination, which is processed by a specific recombination enzyme. This ‘cut-
and-paste’ process uses two specific and inverted DNA sequences to alternate silent genes 
behind a functional promoter (203). There are three well described systems where a single 
gene is placed behind a functional promoter while all other genes are silent and they include 
the vsa gene family of M. pulmonis (220, 221), the vsp genes family of M. bovis (222, 223) 
and the vpma gene family of M. agalactiae (224, 225). All of these bacteria have a site-
specific recombinase that recognizes a specific short DNA sequence as a target for 
rearrangement lying adjacent to the phase-variable locus (226).  
      
Homologous recombination  
 The third type of genetic mechanisms that has been described is homologous 
recombination which can be non-reciprocal, reciprocal, or intra-chromosomal (203). Non-
reciprocal recombination or gene conversion has been demonstrated in the phase-variable 
vlhA gene family of M. synoviae and the MgPa enconding gene of M. genitalium while 
reciprocal recombination has been reported in the MgPar elements of M. genitalium (227–
231). The vlhA family of M. synoviae consists of a single transcriptionally active unit and 
multiple homologous pseudogenes, lacking a coding sequence, located 5’ to the vlhA gene. 
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Antigenic variation occurs from unidirectional recombination between the donor psuedogene 
and the functional vlhA, resulting in the duplication of the pseudogene and total loss of the 
previously expressed gene. (227, 232). Intrachromosomal recombination has been reported 
for the vsp locus of M. bovis, which results in the generation of a chimeric variable 
lipoprotein (223). Each potential vsp is preceded by a homologous sequence that serves as 
the region for site specific DNA inversion (223).   
 
Epitope masking and unmasking 
 The fourth mechanism of phenotypic variation, epitope masking and un-masking 
demonstrates how a constitutively expressed gene could contribute to the plasticity of the cell 
surface (203). This process involved one constitutively expressed antigen and a phase 
variable counterpart which may not actually be the target of the host immune repose. During 
this process, the phase variable, surface exposed component can physically mask another 
surface antigen. This has been descried for the P56 and P120 proteins of M. hominis where 
the phase variable P120 is able to mask the constitutively expressed P56 (203).  
This process has also been described in detail for the previously discussed phase 
variable vlp genes of M. hyorhinis. The products of three genes, vlpA, B, and C are subjected 
to size variation though the intragenic expansion and/or contraction of tandem repeat regions, 
resulting in long and short variation of M. hyorhinis. Those expressing the long variants are 
completely resistant to immune serum antibodies where the short version variants are not. 
The target of the serum antibodies are not the vlp genes, but rather another neighboring 
surface exposed molecule that is masked by the expression of the long vlp variant and 
exposed when the short vlp variant is expressed (209).   
33 
 
 These changes, regardless of the specific mechanisms, allow for the rapid adaptations 
to the changing environment, helping the organisms evade host immune responses and 
express the most advantageous suite of genes to best persist in the current environment.   
 
 
 
Section 5: Mycoplasma Transcriptomics 
 
 In order to further elucidate the pathogenic mechanisms employed by these infectious 
mycoplasma species, there has been significant effort in the field to understand the 
transcriptomics of the organism, both in-vitro and in-vivo. The lack of obvious homologs of 
traditional bacterial transcriptional regulators and signaling factors had initially led to the 
thought that mycoplasmas were unable to regulate transcription by conventional 
mechanisms. This absence, combined with the single identified sigma factor, has led to the 
supposition that differences in gene expression in mycoplasma species are due to population 
selection and heterogeneity rather than more traditional mechanisms.  
Using microarray analysis, it has been demonstrated that the human pathogen, M. 
pneumoniae up-regulates the expression of 47 genes, including the conserved heat shock 
genes dnaK, ionA, and clpB when the organism was incubated in heat shock conditions 
(43°C) for 15 mintues (233).It has also been reported that the porcine pathogen, M. 
hyopneumoniae differentially expresses 27 different genes when the organism is exposed to 
low iron growth conditions (234) and undergoes significant transcriptional changes in 
response to growth in heat shock conditions and in the presence of oxidative stress (235, 
34 
 
236). Of particular importance, was a study conducted by Cecchini et al (237) where RNA 
was extracted  from M. gallisepticum cells co-cultured with MRC-5 human lung fibroblast 
cells for one hour. In comparison to control cells, M. gallisepticum displayed 58 genes that 
were differentially expressed when interacting with the human lung cells. The incubation 
time of this study was only one hour, a timeframe less than that of the generation time of a 
mycoplasma cell, suggesting that the observed changes in gene expression where, in fact, a 
result of exposure to lung cells and not a result of the outgrowth of a subpopulation.         
 In a comprehensive RNA sequencing analysis, using a combination of spotted arrays, 
strand-specific tilling arrays, and transcript sequencing, looking at differential gene 
expression in M. pneumoniae, Guell et al reported differential gene expression in a wide 
variety of conditions including increased temperature, varying pH, minimal media, and 
antibody pressure (238). Of interest, it was reported that there were frequent antisense and 
alternate transcripts and multiple regulators per gene indicating a very dynamic and complex 
transcriptome that is similar to conventional bacteria such as Escherichia coli and Bacillus 
subtilis. (238). 
Additional transcriptomic studies in mycoplasma species have found heat shock 
proteins up-regulated in M. gallisepticum upon exposure to increased temperatures (239), up-
regulation of genes important in the virulence (cysP, nanH, vlhA, and a nuclease) of M. 
synoviae upon co-incubation with chicken chondrocytes (240), and differential expression of 
lipoproteins and nutrient acquisition genes in M. hominis upon exposure to human dendritic 
cells (241). 
A recent study was conducted by Ron et. al., to identify candidate targets proteins 
associated with infection by using in-vivo induced antigen technology (IVIAT). This study 
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showed that there were 13 proteins preferentially expressed during in-vivo infection 
including previously identified virulence factors, GapA, PlpA, Hlp3, VlhA 1.07, and VlhA 
4.01. In addition it was also found that several transport and translation related proteins and 
the chaperone protein GroEL were also preferentially expressed in an in-vivo infection (242).   
 Collectively these data demonstrate that mycoplasma species do, in fact, have the 
ability to alter their transcription in response to external stimuli and may undergo significant 
changes, including the up-regulation of virulence related genes, in response to changes in the 
environment and exposure to potential host cells.  
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Hypothesis and Specific Aims 
 
 
Hypothesis  
 The phase-variable vlhA gene expression profile of M. gallisepticum will change over 
the course of early infection in the natural host in a coordinated, non-random manner. 
 
Specific Aims 
 
Specific aim 1: Investigate and characterize the vlhA gene expression profile of M. 
gallisepticum before and during the course of early infection in the natural  host.  
 
 
Specific aim 2: Determine the changes in the vlhA gene expression profile in M. 
gallisepticum  recovered directly from the trachea mucosa of infected chickens and serially 
passed in-vitro in a nutritive medium. The second goal of this aim will be to determine the 
necessity of exactly 12 GAA trinucleotide repeats for the expression of any given vlhA.  
 
Specific aim 3:  Determine and characterize the M. gallisepticum vlhA trnscriptional profile 
over of the course of early infection when expressing a different initial predominant vlhA at 
time of challenge. 
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Abstract 
Mycoplasma gallisepticum is the primary etiologic agent of Chronic Respiratory 
Disease in poultry, a disease largely affecting the respiratory tract and causing significant 
economic losses worldwide. Immunodominant proteins of the variable lipoprotein and 
hemagglutinin (vlhA) gene family are thought to be important for mechanisms of M. 
gallisepticum-host interaction, pathogenesis, and immune evasion, but their exact role and 
the overall nature of their phase variation are unknown. To better understand these 
mechanisms, we assessed global transcriptomic vlhA gene expression directly from M. 
gallisepticum populations present on tracheal mucosae during a seven day experimental 
infection in the natural chicken host. Here we report differences in both dominant and minor 
vlhA gene expression throughout the first week of infection and starting as early as day one 
post infection, consistent with a functional role not dependent on adaptive immunity for 
driving phase variation. Notably, data indicated that, at given timepoints, specific vlhA genes 
were similarly dominant in multiple independent hosts, suggesting a non-stochastic temporal 
progression of dominant vlhA gene expression in the colonizing bacterial population. The 
dominant expression of a given vlhA gene was not dependent on presence of 12-copy GAA 
trinucleotide repeats in the promoter region and did not revert back to the predominant vlhA 
when no longer faced with host pressures. Overall, these data indicate that vlhA phase 
variation is dynamic throughout the earliest stages of infection and that the pattern of 
dominant vlhA expression may be nonrandom and regulated by previously unrecognized 
mechanisms.  
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Introduction 
 
Mycoplasma gallisepticum, the primary etiologic agent of Chronic Respiratory Disease 
(CRD) in poultry, is highly transmissible and causes severe inflammation of trachea, lungs, 
and air sacs, ultimately resulting in an overall reduction in weight gain and egg production in 
infected chickens. M. gallisepticum is pathogenic in other species, causing infectious sinusitis 
in turkeys and conjunctivitis in house finches (2, 146). Aside from primary attachment 
proteins GapA and CrmA, fibronectin binding proteins PlpA and Hlp3, sugar transport 
permease MalF, and dihydrolipoamide dehydrogenase Lpd, little is understood about specific 
bacterial factors affecting survival and persistence of this important avian pathogen in its 
natural host (34, 194, 199, 200).  
The lack of obvious homologs of traditional bacterial transcriptional regulators and 
signaling factors had previously led to the thought that mycoplasmas were unable to regulate 
transcription by conventional mechanisms. However, M. gallisepticum exhibits differential 
gene expression in response to co-incubation with MRC-5 human lung fibroblasts(237) and 
in response to various stress conditions (239, 243). These data suggest that changes in 
transcription are indeed occurring as mycoplasmas respond to external stimuli and that the 
regulation is, in fact, more dynamic then originally hypothesized, with genes potentially 
affected by multiple regulators (238).  
Potentially important for M. gallisepticum pathogenesis is the variable lipoprotein and 
hemagglutinin (vlhA) family, consisting of  43 genes distributed across 5 loci and totaling 
just over 10% of the entire genome in strain Rlow (195). Previous studies have indicated that 
M. gallisepticum vlhA expression is dependent on the presence of exactly 12 GAA 
trinucleotide repeats upstream of the gene (213–216). It has also been hypothesized that M. 
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gallisepticum vlhA phase variation is stochastic, driven by anti-VlhA antibody-mediated 
negative selection of the initial population and resulting in random outgrowth of bacterial 
subpopulations expressing alternate vlhA(117). If that were correct, we would expect to see 
varying patterns of vlhA expression from the individual chickens at each time point. 
  The function of VlhA proteins is still unknown, but it has been speculated to involve 
immune evasion during infection (116), and variation in vlhA gene content has been loosely 
associated with virulence (153).While there have been efforts to understand the antigens 
expressed by M. gallisepticum in-vivo (242), there has not yet been a comprehensive global 
scale, in-vivo transcriptome study of M. gallisepticum in response to the natural host over the 
course of early infection. Previous studies have assessed selected in-vivo vlhA gene 
expression changes using monoclonal antibodies, however methods for comprehensive vlhA 
analysis were not yet available (213, 214). Now using next-generation sequencing, which 
enables comprehensive gene expression assessment at the nucleotide level, we present results 
indicating changes in vlhA expression of M. gallisepticum sampled directly from the tracheas 
of the experimentally infected chickens over the course of a seven-day infection. 
 
 
Materials and Methods 
 
Animals  
Four-week-old female specific-pathogen-free White Leghorn chickens (SPAFAS, 
North Franklin, CT, USA) were received and divided randomly into groups, placed in 
HEPA-filtered isolators, and allowed to acclimate for one week. Non-medicated feed and 
41 
 
water were provided ad libitum throughout the experiment. All animal studies were 
performed in accordance with approved UConn IACUC protocol number A13-001. 
 
Chicken infection  
Stocks of M. gallisepticum strain Rlow (passage 17) were grown overnight at 37°C in 
complete Hayflick’s medium until mid-log phase was reached as indicated by a color shift 
from red to orange. Bacterial concentrations were determined by the OD620 and 10-fold serial 
dilutions were conducted to confirm viable color changing unit titers. Bacteria were pelleted 
by centrifugation at 10,000 x g for 10 min and resuspended in Hayflick’s complete medium. 
Chickens were challenged intratracheally as previously described (194) with 1 x 108 
CFU/200 µl. 
 
RNA extraction 
  Five infected chickens were humanely sacrificed daily for a total of seven days. After 
sacrifice, tracheas were excised and total RNA was extracted from each individual trachea by 
washing the lumen with 1 mL TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA 
was then purified using the Zymo Direct-zol RNA Miniprep Kit (Zymo Research 
Corperation, Irvine, CA, USA) and standard PCR was conducted to ensure the RNA preps 
were free of any DNA. RNA was quality-checked using an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) and high quality samples with RNA integrity 
numbers (RIN) >8 were utilized to construct cDNA libraries. 
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To enrich for bacterial RNA, total RNAs were subjected to a polyA depletion step to 
remove the eukaryotic mRNA using the NEBNext Poly(A) mRNA Magnetic Isolation 
Module (New England Biolabs, Ispwich, MA, USA). Briefly, 5 μg of total RNA combined 
with an equal volume of bead binding buffer was bound to the poly-T oligo-attached 
magnetic beads at 65°C for five minutes. The remaining supernatant was collected, cleaned 
and concentrated using the Zymo clean and concentrator -25 kit (Zymo Research 
Corperation) and eluted in 25μl  RNase-free water.  
Both prokaryotic and eukaryotic ribosomal RNA were removed from 2.5 μg of poly-
A depleted RNA using the RiboZero Magnetic Gold kit (Epidemiology) (Illumina Inc., San 
Diego, CA, USA) following the manufacturer’s instructions. Each rRNA depleted RNA 
sample obtained after cleaning and concentrating with the Zymo clean and concentrator -25 
kit (Zymo Research Corporation) was eluted in 25 μl of RNase free water and used to create 
a cDNA library. 
 
Illumina Sequencing  
The cDNA libraries were created using the Illumina TruSeq Stranded mRNA Library 
Preparation Kit (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s 
instructions starting at “Make RFP” (step 14, p.56) of the Illumina TruSeq RNA Sample 
Preparation v2 (HT) protocol. Briefly, 10-400 ng of purified mRNA was fragmented and 
used to synthesize first-strand cDNA using reverse transcriptase and random hexamer 
primers. Second-strand cDNA synthesis was performed using dUTP, DNA polymerase, and 
RNase. The products were amplified by PCR and purified after end repair and adaptor 
ligations.  
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The cDNA libraries were assessed for quantity using the Qubit 2.0 fluorometer 
(Invitrogen) and correct fragment size (~260 bp) using the Agilent TapeStation 2200 (Agilent 
Technologies). Libraries were then normalized to two nM, pooled, denatured, and sequenced 
on a NextSeq500 Sequencing platform (Illumina Inc.) using a 75 bp paired-end approach. 
 
RNA-seq Analysis  
Fastq data were assembled and mapped, and differential gene expression assessed, 
using Rockhopper, an RNAseq analysis program with algorithms specifically designed for 
the bacterial gene structures and transcriptomes 
(http://cs.wellesley.edu/~btjaden/Rockhopper/) (244, 245).   Bowtie2 parameters allowing 0 
mismatches were used to map sequence reads to the Rlow genomic template (195). The data 
were normalized by the standard method of determining the ratio of reads per kilobase of 
transcript per million reads mapped (RPKM), allowing for comparisons both within and 
between samples. The fold change was determined from the log2 transformation of the 
RPKM between two samples. The differential gene expression was determined by pair-wise 
comparisons between the normalized expression values of a given vlhA gene between two 
different days. The program-generated p-value was used to determine the significance of the 
differential gene expression by calculating q-values based on the Benjamini–Hochberg 
correction with a false discovery rate <1%. Differences in expression values were considered 
significant when q < 0.02 (245). 
 
Sequencing of culture-passed bacteria 
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Mycoplasma cultures recovered from tracheas of the experimentally infected birds at 
day seven postinfection were passed five or ten times in Hayflick’s complete medium. 
Cultures were then grown to mid-log phase for DNA extraction using Chelex reagent 
(BioRad, Hercules, CA, USA) or RNA extraction, enrichment, and sequencing as was 
described with the trachea samples above.  
Targeted sequencing of vlhA 2.02 gene promoter sequences to query GAA repeat 
copy number was performed directly on specific PCR amplicons. PCR primers targeting the 
vlhA 2.02 promoter region designed using the M. gallisepticum R(low) genomic sequence 
(GenBank accession no. AE015450) (195) were as follows: forward 5’-
GATGAGATTATCAAGCTTTTAGATG-3’ and reverse  
5’-CTGAACGAATCAAAGAGTTACAGC-3’. PCR was performed using Amplitaq 
(Invitrogen), 20 pmol of each primer and 200-300 ng DNA with the following cycling 
conditions: 94°C for 5 min, followed by 40 cycles at 94°C for 15 sec, 54°C for 30 sec, and 
72°C for 1 min with a final extension of 72°C for 10 min. Amplicons were purified using the 
MinElute Reaction Cleanup Kit (Qiagen, Valencia, CA, USA) to remove excess primers. 
Sequencing was performed using 2 μl BigDye Terminator Mix (Invitrogen), 10 pmol 
of primer, and 300 ng of DNA (246).  Excess dye terminators were removed with AutoSeq 
G-50 spin columns (Amersham Biosciences, Piscataway, NJ, USA), and the sequencing was 
performed by the University of Connecticut Biotechnology Center. Using Sequencher 
software (Gene Codes, Ann Arbor, MI, USA), the sequences were compared to the Rlow 
genome and the number of GAA trinucleotide repeats upstream of the gene start codon were 
assessed.  
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Results 
 
M. gallisepticum input vlhA expression 
 In broth grown M. gallisepticum strain Rlow input cultures, data here indicated that 31 
vlhAs were expressed with an average normalized expression value of 719. vlhA 3.03 was the 
predominant vlhA expressed in this culture, with an RPKM value >12,000 (Fig.1). This vlhA 
is preceded by exactly 12 GAA repeats (11), a characteristic previously thought to be 
necessary for expression (12-15). vlhA 3.03 was not the only vlhA expressed, however,  as 
several other vlhAs, including 2.02, 5.06, and 4.07, were expressed at levels (RPKM of 1500 
– 2300) above the average RPKM (1455) of all genes in the genome that were expressed. 
This indicated that, while vlhA 3.03 expression predominated, additional vlhAs that were not 
preceded by 12 GAA repeats were expressed at minor levels in the cultured experimental 
input population.   
 
M. gallisepticum vlhA expression over the course of infection  
 Over the course of the seven-day infection, the vlhA expression profile changed 
dramatically. The expression of vlhA 3.03 showed an initial increase at day one postinfection 
and then decreased daily throughout the experiment (Fig 2). Over the course of infection, 
there was a 34-fold total decrease in vlhA 3.03 expression (q<0.0001), with the largest 
change being a 4.5-fold decrease between days 5 and 6 postinfection  (q< 0.0001).  
While expression of vlhA 3.03 decreased early in infection, expression of vlhA 4.07 
and its tandem repeat, vlhA 4.07.6 began to increase as early as one day postinfection. These 
expression levels peaked at two days postinfection (3.7-fold higher than input culture) before 
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decreasing over the remainder of the seven-day infection (Fig 2). Similarly, as vlhA 4.07 and 
4.07.6 decrease in expression, vlhA 4.08 and its tandem repeat, vlhA 4.07.1 showed increased 
expression until peaking at seven days postinfection with 31-fold higher (q<0.0001) 
expression than levels of input cultures (Fig. 2). Finally, there was an initial increase in vlhA 
5.05 expression at one day postinfection, followed by decreasing expression through the time 
course. The vlhA expression profile observed here at day seven postinfection was consistent 
with that of a previous pilot experiment (data not shown). Taken together, these changes in 
vlhAs expression were not completely random, and appeared to be relatively coordinated as 
similar vlhA profiles were seen in five independently infected birds at each time point 
postinfection.  
 
M. gallisepticum vlhA expression in recovery cultures 
 From infected birds sacrificed seven days postinfection, M. gallisepticum was 
recovered directly from tracheas into Hayflick’s complete medium and serially passed in-
vitro. After either five or 10 passages, M. gallisepticum populations were predominantly 
expressing vlhA 2.02 with an average RPKM value of 8463, a 4.4-fold increase relative to 
vlhA 2.02 expression observed directly on tracheal mucosae at seven days postinfection  (q< 
0.0001) (Fig 3A). The M. gallisepticum recovered after one passage in-vitro displayed a 
transitional vlhA profile with vlhA 3.03 and 2.02 increasing in expression and vlhA 4.07.1 and 
4.08 decreasing in expression (Data not shown). These data suggest the expression of vlhA 
2.02 is favorable for the pathogen after recovery from the host trachea and passage in a 
nutritive medium. Several other vlhAs, including vlhA 3.03, were also expressed in the 
recovery cultures, but at levels much lower than vlhA 2.02. Interestingly, vlhA 3.03 was 
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expressed at a much lower, non-dominant level (4.5-fold) than in the initial input culture (Fig 
3A).   
 When the promoter region upstream of the highly expressed vlhA 2.02 gene from the 
recovery cultures was PCR amplified and sequenced, data revealed only a single GAA 
trinucleotide upstream of the start codon, suggesting that 12 GAA repeat copies might not be 
essential for the expression of a given vlhA, at least in the in-vitro culture following direct 
recovery from the trachea (Fig 3B). Furthermore, we observed no changes in the genomic 
nucleotide sequence upstream of vlhA 2.02 in the cultures recovered from the infected 
animals and passed in-vitro compared to the broth grown input culture.     
 
Discussion 
 This study has demonstrated the global population changes in M. gallisepticum vlhA 
gene expression assessed directly from tracheas of experimentally infected chickens over the 
course of a seven day infection. It was important to recover the M. gallisepticum RNA 
directly from the trachea into the TRIzol reagent to minimize the time between collection and 
extraction, as we observed significant changes in the gene expression profile of M. 
gallisepticum after just one single passage in culture medium (data not shown). This study 
design allowed for the capture of the most accurate representation of the vlhA profile in-vivo 
at each time point during the infection process.  
  These observed changes in expression are likely not antibody mediated, as the decrease 
in expression of vlhA 3.03 is seen as early as two days postinfection, well before the 
formation of specific antibodies(193). This finding is in agreement with a previous study that 
demonstrated that vlhA expression in infected chickens switches prior to the host mounting 
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an antibody response (214). However, this study greatly expands on those initial observations 
to include the expression status of all of the vlhAs over the early course of infection. 
   These findings are significant as they imply that the driving force behind the shift in 
vlhA expression is not controlled entirely by the adaptive immune system. These data suggest 
that another mechanism is, at least in part, controlling changes in expression of the vlhA 
genes in-vivo.   
  It is possible that early phase variation could be driven, in part, by the alterations in the 
cellular architecture of the tracheas during infection. As the infection progresses, the host 
cells experience denuding of cilia, squamous cell metaplasia, and eventual destruction of the 
host cell membranes. It is possible that the M. gallisepticum vlhA expression is changing in 
response to these alterations and the pathogen is expressing a specific set of vlhAs to best 
persist in the current environment. Consistent with the hypothesis that M. gallisepticum vlhA 
expression is nonrandom and follows progression of pathogenesis in the host, vlhA 1.07 and 
4.01 reported by Ron et al. (242) to express significant antigens at two to five weeks 
postinfection were not predominantly expressed within one week postinfection as reported 
here.  
 Data here indicate that despite expressing different vlhAs in the host at day seven 
postinfection, vlhA 2.02 is the predominant vlhA expressed in the M. gallisepticum 
population following recovery and passage in Hayflick’s complete medium. Unanticipated 
was the dominance of vlhA 2.02 and the lack of reversion to predominant vlhA 3.03 
expression observed in the broth grown input culture. However, in these recovery cultures, 
vlhA 2.02 was also accompanied by the expression (albeit at lower levels) of several other 
vlhAs in the population, including vlhA 3.03 and 5.13, suggesting that more than one vlhA is 
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expressed at a given time point in the population. These data also indicate that M. 
gallispticum may favor the expression of several vlhAs (vlhA 3.03, 2.02, and 5.13) when no 
longer faced with the pressures of surviving in the airway of the host 
 Data here also demonstrated that 12 GAA trinucleotide repeats are not essential for the 
expression of a given vlhA, since the vlhA 2.02 highly expressed in the recovery samples 
does not contain 12 GAA repeats in upstream sequences. It had previously been hypothesized 
that 12 GAA repeats were necessary for expression of a given vlhA because it allowed for the 
correct spacing between flanking sequences for necessary accessory factors to bind, as M. 
gallisepticum does not possess a robust consensus sequence at -10 and -35 (216). The 
observed expression of vlhA genes without the 12 GAA repeats upstream suggest that there 
may be another mechanism at play that is responsible, at least in part, for the regulation of 
the vlhA expression in M. gallisepticum.      
These results, revealing global vlhA expression changes over the course of early 
infection, are important in elucidating mechanisms of persistence, colonization, and overall 
pathogenesis of M. gallisepticum in the natural host. Full and complete understanding of 
these mechanisms will provide information likely to be critical for development of rationally 
designed M. gallisepticum therapeutics and vaccines. 
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Figure 1. The vlhA expression profile of the broth grown M. gallisepticum input cultures as 
determined from RNA sequencing.  
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Figure 2. The vlhA expression profile of M. gallisepticum extracted directly from tracheas of 
experimentally infected birds over the course of the seven day infection as determined 
though RNA sequencing. Each data point is an average RPKM value from five animals (with 
the exception of the broth sample). Error bars show SEM. Key statistically significant 
changes between two time points are indicated by paired upper and lower case letters for the 
following genes: vlhA 3.03 (A/a and A’/a’), and vlhA 4.07.1/4.08 (B/b). 
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Figure 3. The vlhA expression of the M. gallisepticum recovered and cultured at five (5’) or 
ten (10’) passes from the tracheas of the two different infected birds at seven days 
postinfection  (A). Only vlhAs with an average RPKM >100 are displayed. The sequence of 
the region upstream of the highly expressed vlhA 2.02 in the cultures recovered from the 
infected birds (B).  
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The vlhA profile of Mycoplasma gallisepticum predominantly expressing an alternate 
vlhA over a two day in-vivo infection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
Abstract 
 
Mycoplasma gallisepticum is the primary etiologic agent of Chronic Respiratory 
Disease in poultry, a disease largely affecting the respiratory tract and causing significant 
economic losses worldwide. Proteins of the variable lipoprotein and hemagglutinin (vlhA) 
gene family are thought to be important for mechanisms of M. gallisepticum-host interaction, 
pathogenesis, and immune evasion, but their exact role and the overall nature of their phase 
variation are unknown. To better understand these mechanisms, we assessed global 
transcriptomic vlhA gene expression directly from M. gallisepticum populations present on 
tracheal mucosae during an experimental infection in the natural chicken host with a strain 
expressing an alternate dominant vlhA. Here we report that the  in vivo vlhA expression 
profile of M. gallisepticum when chickens are infected with a culture predominantly 
expressing vlhA 2.02 is similar to that seen when the M. gallisepticum predominantly 
expressing vlhA 3.03 is used for infection during early stages of infection. This indicates that 
the progression of vlhA expression, especially the initial predominantly expression of vlhA is 
likely important during the earliest stages of the infection process. 
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Introduction 
 
 Mycoplasma gallisepticum, a highly transmissible avian pathogen, contributes to 
chronic respiratory disease (CDR), a pathological syndrome largely affecting the respiratory 
tracts of poultry causing inflammation of the air sacs, lungs, and trachea causing significant 
monetary losses world-wide (2). M. gallisepticum has also been linked to infectious sinusitis 
in turkeys and severe conjunctivitis in house finch(2, 247).  
 Despite much effort, little is completely understood about the mechanisms of survival 
and persistence or pathogenic mechanisms employed by this organism (34, 194, 237, 199, 
200, 242). Potentially important in the virulence of the organism is the phase-variable 
lipoprotein hemagglutinin gene family (vlhA)(195) as they have been shown to differ in both 
size and genomic location in strains varying in levels of virulence (153). Initial studies have 
reported that vlhA expression is stochastic, and due to radom outgrowth after anti-VlhA 
antibody mediated negative selection (117). It has also been reported that the expression of a 
single vlhA gene occurs only when that gene is preceded by exactly 12 GAA triucleotide 
repeats in the promoter region (213, 215, 216, 224). However, despite this report, a recent 
study has shown that at given timepoints, specific vlhA genes were similarly dominant in 
multiple independent hosts, suggesting a non-stochastic temporal progression of dominant 
vlhA gene expression and that the expression was not completely dependent on the presence 
of 12 GAA trinuclotide repeats (248).  
 Here, using next-generation sequencing, we extend the understanding of vlhA gene 
expression, specially the importance of the vlhA 3.03, the initial immuno-dominat vlhA at one 
56 
 
day post-infection. We report the results of the global vlhA gene expression profile when the 
input population is expressing an alternate dominant vlhA, vlhA 2.02.          
  
 
Materials and Methods 
 
Animals  
Four-week-old female specific-pathogen-free White Leghorn chickens (SPAFAS, 
North Franklin, CT, USA) were received and divided randomly into groups, placed in 
HEPA-filtered isolators, and allowed to acclimate for one week. Non-medicated feed and 
water were provided ad libitum throughout the experiment. All animal studies were 
performed in accordance with approved UConn IACUC protocol number A13-001. 
 
Chicken infection  
M. gallisepticum R strain cultures stabilized to express an alternate vlhA (vlhA 2.02) 
have been identified (248)  were used as the input cultures in. As a positive control, M. 
gallisepticum strain Rlow (passage 17) were also used for inoculation.10-fold serial dilutions 
were conducted to confirm viable color changing unit titers. Bacteria were pelleted by 
centrifugation at 10,000 x g for 10 min and re-suspended in Hayflick’s complete medium. 
Chickens were challenged intratracheally as previously described (248). 
 
RNA extraction 
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  Four infected chickens from each group were humanely sacrificed at day 1 and day 2 
post infection. After sacrifice, tracheas were excised and total RNA was extracted from each 
individual trachea by washing the lumen with 1 mL TRIzol reagent (Invitrogen, Carlsbad, 
CA, USA). Total RNA was then purified using the Zymo Direct-zol RNA Miniprep Kit 
(Zymo Research Corperation, Irvine, CA, USA) and standard PCR was conducted to ensure 
the RNA preps were free of any DNA. RNA was quality-checked using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and high quality samples with 
RNA integrity numbers (RIN) >8 were utilized to construct cDNA libraries. 
M. gallisepticum RNA was enriched as previously described (248). Briefly, total 
RNAs were subjected to a polyA depletion step to remove the eukaryotic mRNA using the 
NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, Ispwich, MA, 
USA). Briefly, 5 μg of total RNA combined with an equal volume of bead binding buffer 
was bound to the poly-T oligo-attached magnetic beads at 65°C for five minutes. The 
remaining supernatant was collected, cleaned and concentrated using the Zymo clean and 
concentrator -25 kit (Zymo Research Corperation) and eluted in 25μl  RNase-free water.  
Both prokaryotic and eukaryotic ribosomal RNA were removed from 2.5 μg of poly-
A depleted RNA using the RiboZero Magnetic Gold kit (Epidemiology) (Illumina Inc., San 
Diego, CA, USA) following the manufacturer’s instructions. Each rRNA depleted RNA 
sample obtained after cleaning and concentrating with the Zymo clean and concentrator -25 
kit (Zymo Research Corporation) was eluted in 25 μl of RNase free water and used to create 
a cDNA library. 
 
Illumina Sequencing  
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The cDNA libraries were created using the Illumina TruSeq Stranded mRNA Library 
Preparation Kit (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s 
instructions starting at “Make RFP” (step 14, p.56) of the Illumina TruSeq RNA Sample 
Preparation v2 (HT) protocol. Briefly, 10-400 ng of purified mRNA was fragmented and 
used to synthesize first-strand cDNA using reverse transcriptase and random hexamer 
primers. Second-strand cDNA synthesis was performed using dUTP, DNA polymerase, and 
RNase. The products were amplified by PCR and purified after end repair and adaptor 
ligations.  
The cDNA libraries were assessed for quantity using the Qubit 2.0 fluorometer 
(Invitrogen) and correct fragment size (~260 bp) using the Agilent TapeStation 2200 (Agilent 
Technologies). Libraries were then normalized to two nM, pooled, denatured, and sequenced 
on a NextSeq500 Sequencing platform (Illumina Inc.) using a 75 bp paired-end approach. 
 
RNA-seq Analysis  
Fastq data were assembled and mapped, and differential gene expression assessed, 
using Rockhopper, an RNAseq analysis program with algorithms specifically designed for 
the bacterial gene structures and transcriptomes 
(http://cs.wellesley.edu/~btjaden/Rockhopper/) (244, 245).   Bowtie2 parameters allowing 0 
mismatches were used to map sequence reads to the Rlow genomic template (195). The data 
were normalized by the standard method of determining the ratio of reads per kilobase of 
transcript per million reads mapped (RPKM), allowing for comparisons both within and 
between samples. The fold change was determined from the log2 transformation of the 
RPKM between two samples. The differential gene expression was determined by pair-wise 
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comparisons between the normalized expression values of a given vlhA gene between two 
different days. The program-generated p-value was used to determine the significance of the 
differential gene expression by calculating q-values based on the Benjamini–Hochberg 
correction with a false discovery rate <1%. Differences in expression values were considered 
significant when q < 0.02 (245).  
 
 
 
Results 
 When chickens are experimentally challenged with an M. gallisepticum strain 
predominantly expressing an alternate vlhA, the vlhA expression profile of the bacteria 
recovered from the tracheal mucosa is very similar to that of a wild type strain expressing 
vlhA 3.03 predominantly (Fig 1).   
 In the M. gallisepticum recovered from experimentally infected chickens, we 
observed a sharp increase in the expression of the vlhA 3.03 at one day post infection with a 
14.8-fold increase in expression compared to the vlhA 3.03 gene expression in the input 
population. Followed by this sharp increase, was a 6.1-fold decrease in expression of vlhA 
3.03 by two days post infection Fig 1 and Table 1). This pattern was very similar to that of 
the initial wild-type input culture in which that population was predominantly expressing 
vlhA 3.03 (see chapter 2).  
 Additionally, we observed a similar pattern of expression with vlhA 4.07 and its 
tandem repeat vlhA 4.07.6, where there was a 80.1-fold and 78.7-fold increase compared to 
the input population, respectively, in the expression at day one post infection. This was then 
followed by a 5.8- and 5.4-fold decrease in expression by day two post infection (Fig1 and 
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Table 1). This pattern is also observed when the wild type input cultures are predominantly 
expressing vlhA 3.03 (see chapter 2).    
 Surprisingly, vlhA 2.02, the predominant vlhA expressed in the challenge culture, 
stayed relatively stable through one day post infection displaying only a slight 1.1-fold 
increase in expression. However, the expression level of vlhA 2.02 showed a 9.7-fold 
reduction in expression level by two days post infection (Fig 1 and Table 1). This differs 
from the vlhA expression profile of wild type M .gallisepticum initially expressing vlhA 3.03 
predominantly. When vlhA 3.03 was predominantly expressed in the input population, vlhA 
2.02 did not show an expression level above background at any point during the seven day 
infection study (see chapter 2).    
 
Discussion 
 Here we report the initial vlhA expression profile of M. gallisepticum predominantly 
expressing vlhA 2.02 recovered from the chicken tracheas during the early course of 
experimental infection. The vlhA expression profile was very similar to that of the wild type 
M. gallisepticum strains with a sharp increase in the expression of vlhA 3.03 at one day post 
infection and a decrease in expression by two days post infection.  
 These data suggest that vlhA 3.03 is likely very important in the early infection 
process of M. gallisepticum as it is highly expressed at one day post infection regardless if it 
was predominant in the initial culture used for challenge or not.   
 Additionally, we observed an increase in the expression of vlhA 4.07 and 4.07.6 at 
one day post infection, a pattern also observed when the initial input culture was 
predominantly expressing vlhA 3.03. This suggests that, while not the predominant vlhA 
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genes expressed, they still may play a vital role for M. gallisepticum in the earliest stages of 
infection.  
 It is important to note that, while the input population used in this second study was 
predominantly expressing vlhA 2.02, vlhA 3.03 was still expressed, albeit at a much lower 
level, in this population. It is possible that the perceived increase in the expression of vlhA 
3.03 at day one post infection is due to the fact that only those M. gallisepticum expressing 
vlhA 3.03 were able to colonize the trachea at that time. Either way, these data emphasize the 
importance of the predominant expression of vlhA 3.03 in the earliest stages of infection.  
 In totality these data demonstrate that even when the predominant vlhA expression is 
altered, M. gallisepticum still undergoes the same non-stochastic temporal progression of 
expression over the earliest stages of infection. This suggests that progression of vlhA 
expression is likely important in the initial stages of the infection process in the chicken 
trachea.  
 Further insight into these patterns of expression may lead to a more complete 
understanding of the pathogenic mechanisms employed by M. gallisepticum during early 
stages of the infection process.        
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Figure 1. The vlhA gene expression profile of the M. gallisepticum strain predominantly 
expressing vlhA 2.02 from the tracheal mucosa of experimentally infected birds over a two-
day infection.  
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Table 1. The fold change of select vlhA genes over from the M. gallisepticum strain 
predominantly expressing vlhA 2.02 from the tracheal mucosa of experimentally infected 
birds over a two-day infection.  
 
vlhA gene Fold Change 
 Broth vs Day 1 Day 1 vs Day 2 
vlhA 3.03 +14.8 -6.1 
vlhA 4.07 +80.1 -5.8 
vlhA 4.07.6 +78.7 -5.4 
vlhA 2.02 +1.1 -9.7 
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CHAPTER 4 
 
 
 
 CONCLUSIONS AND DISCUSSION 
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 Collectively, these data significantly further our understanding of the M. 
gallisepticum phase-variable vlhA gene expression, showing that the vlhA genes exhibit a 
non-stochastic temporal progression of expression and altering the starting vlhA does not 
alter the predominant expression of vlhA 3.03 at one day post infection.  
We observed changes in vlhA gene expression as early as 1-2 days post infection, 
well before the formation of specific antibodies (193), suggesting that the changes observed 
at these earliest stages of infection are not influenced  by the adaptive immune system of the 
host,. However, it is very likely that as the disease progresses, the host adaptive immune 
response will play a role in the vlhA genes expression patterns as it has been demonstrated 
that a change in vlhA expression can be forced in-vitro by the addition of specific antibodies 
(249). These data suggest that another mechanism is, at least in part, responsible for the 
changes in expression of the vlhA genes in-vivo during the earliest stages of the infection 
process.  
It is possible that these changes in vlhA expression could be in response to the 
alterations in the cellular architecture of the tracheas during infection. As the infection 
progresses, the host cells experience denuding of cilia, squamous cell metaplasia, and 
eventual destruction of the host cell membranes. It is possible that the M. gallisepticum vlhA 
expression is changing in response to these alterations and the pathogen is expressing 
successive  specific sets of vlhAs to best persist in the current environment.  
 This is similar to what has been reported in Wolbachia species, a rickettsial bacterium 
which infects invertebrate organisms lacking adaptive immune systems. Wolbachia variable 
surface proteins are involved in host cell attachment and vary their expression in response to 
non-immune environmental pressures (250).  
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 As the function of VlhAs is still unknown at this time, it is also possible that these 
gene products could be functioning in sensing the current environment and relaying messages 
into the cell. It is also possible that these gene products could be involved in the transport of 
essential nutrients and molecules, as these VlhAs are surface exposed. M. gallisepticum 
could be altering expression of vlhAs in response to a change in nutrient availability in the 
current environment.    
 Data here also indicated that the vlhAs exhibit a non-stochastic, temporal progression 
of expression, as vlhAs were similarly dominant in multiple independent hosts in repeated 
studies. This is particularly interesting as previous studies have hypothesized that that vlhA 
expression was stochastic, and due to radom outgrowth after anti-VlhA antibody mediated 
negative selection (214).   
Unanticipated was the dominance of vlhA 2.02 and the lack of reversion to 
predominant vlhA 3.03 expression observed in the broth grown input culture. However, in 
these recovery cultures, vlhA 2.02 was also accompanied by the expression (albeit at lower 
levels) of several other vlhAs in the population, including vlhA 3.03 and 5.13, suggesting that 
more than one vlhA is expressed at a given time point in the population. These data also 
indicate that M. gallispticum may favor the expression of several vlhAs (vlhA 3.03, 2.02, and 
5.13) when no longer faced with the pressures of surviving in the airway of the host. 
Data here also demonstrated that 12 GAA trinucleotide repeats are not essential for 
the expression of a given vlhA, since the vlhA 2.02 highly expressed in the recovery samples 
does not contain 12 GAA repeats in upstream sequences. It had previously been hypothesized 
that 12 GAA repeats were necessary for expression of a given vlhA because it allowed for the 
correct spacing between flanking sequences for necessary accessory factors to bind, as M. 
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gallisepticum does not possess a robust consensus sequence at -10 and -35 (216). The 
observed expression of vlhA genes without the 12 GAA repeats upstream suggests that there 
may be another mechanism at play that is responsible, at least in part, for the regulation of 
the vlhA expression in M. gallisepticum. 
 Additionally, we found that M. gallisepticum strains expressing an alternate dominant 
vlhA still display a very similar expression pattern over the earliest stages of the infection, 
showing a sharp increasing the expression of vlhA 3.03 at one day post infection, followed a 
decrease by two days post infection. Additionally the initial increase in the expression of 
vlhA 4.07 and its tandem repeat, 4.07.6 was observed, followed by the decline in expression 
by two days post infection. These data suggest that vlhA 3.03 may play a critical role in the 
infection process of M. gallisepticum in the trachea of the chicken host as it is consistently 
highly and predominantly expressed at day one post infection regardless of the predominant 
vlhA expressed in the input culture. Additionally, vlhAs 4.07 and 4.07.6 are likely important 
during the earliest stages of the infection process as their increased expression is repeatedly 
observed at day one post infection, regardless of the predominantly expressed vlhA in the 
challenge culture.   
 Taken together these data demonstrate that even when the predominant vlhA 
expression is altered, M. gallisepticum still undergoes the same non-stochastic temporal 
progression of expression over the earliest stages of infection. This suggests that progression 
of vlhA expression is likely important in the initial stages of the infection process in the 
chicken trachea.  
 Specific vlhA gene products are likely to have specific functions; however, the exact 
roles are unknown at this time. These gene products could be involved in attachment to host 
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cells to prevent clearance, sensing of the surrounding environment, or transport of nutrients 
into the cell. Regardless of the function of these products, M. gallisepticum expresses these 
genes in a coordinated, non-random manner over the course of early infection in the chicken 
trachea. This non-stochastic vlhA expression pattern is still displayed in-vivo even when the 
initial challenge culture expression pattern is altered.  
The data suggest that these gene products are important in early infection in the 
natural host and each VlhA (or specific set of VlhAs) may have a unique function. M. 
gallisepticum is likely expressing a specific subset of vlhA genes in order to best persist in the 
current environment. If there were no change in the environment M. gallisepticum is 
persisting in, it appears there is little to no change in the predominant vlhA expressed. For 
example when M. gallisepticum is passed numerous times in-vitro, the predominant vlhA 
gene expression remains stable. However, when it is exposed to the cells of the chicken 
trachea, the vlhA profile begins to change immediately, as early as day one post infection, 
suggesting that M gallisepticum is responding to the change in environment and likely 
expressing a subset of vlhAs  to best persist in that environment.  
Furthermore, once M. gallisepticum is recovered from the trachea of experimentally 
infected chickens and passed in-vitro, the vlhA expression profile changes again, suggesting, 
yet again, that M. gallisepticum is expressing a very specific subset of vlhA genes to best 
survive in the current environment.       
Overall, these data indicate that vlhA phase variation is dynamic throughout the 
earliest stages of infection and that the patterns of dominant vlhA gene expression are 
nonrandom and regulated by a currently unknown mechanism(s). These data also stress the 
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importance of the expression of vlhA 3.03 during the initial stages of infection, furthering our 
understanding of phase variation in M. gallisepticum.  
These results, revealing global vlhA expression changes over the course of early 
infection, are important in elucidating mechanisms of persistence, colonization, and overall 
pathogenesis of M. gallisepticum in the natural host. We can now begin to further understand 
vlhA gene expression and phase variation in M. gallisepticum. Full and complete 
understanding of these patterns of expression will help to provide insight that may be critical 
for the development of rationally designed therapeutics and vaccines.    
 
Future Directions 
Although beyond the scope of this project, it will be beneficial to determine if there is 
tissue specificity for different vlhA genes. For example, it is possible that different vlhA genes 
are dominantly expressed when exposed to varying cell types in tissues of the host, allowing 
for optimal survival in the different tissues. Additionally, as infection with M. gallisepticum 
progresses in the respiratory tract, the architecture of the trachea changes as well as the cell 
type predominating as metaplasia occurs. The M. gallisepticum could be altering the 
predominant vlhA expressed as a response to the changing cell type in the chicken trachea at 
a given time point and expressing the best vlhA to persist in that current environment.  
Examining the global vlhA profile in various host tissues including, air sacs, lungs, and 
oviducts and understanding the driving force behind the changes in vlhA gene expression in 
the trachea would provide valuable information into the specificity of the vlhA expression 
profile.    
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Given that vlhA 3.03 appears to be important in the initial stages of the infection 
process, as it is the predominant vlhA at day one post infection, regardless of what the 
starting predominant vlhA is in the input culture,  it will beneficial to assess the virulence of 
mutants lacking vlhA 3.03 in the natural host. Screening our transposon mutant library, a 
vlhA 3.03 mutant could be identified and used to experimentally challenge chickens and 
assess the virulence of the mutant and to determine the plasticity of the vlhA profile. These 
data would indicate the necessity (or lack thereof) of the expression of vlhA 3.03 to attach, 
colonize, and causes pathology in the respiratory organs of chickens.      
In conjunction with this study, the lab is also sequencing the host RNA obtained from 
the same samples used in this study over the course of early infection. This will allow a 
glimpse into the interplay between the pathogen and its natural host over the initial stages of 
the infection process, furthering our understanding of the pathogenesis of M. gallisepticum 
and how the host responds to that challenge. Assessing these data concurrently could provide 
insight into the host factors that could be playing a role in the non-stochastic temporal 
progression of vlhA expression.  
 Additionally, examining the vlhA profile of live attenuated vaccine strains will 
enhance our understanding of the progression and importance of vlhA gene expression. These 
strains do not cause the same level of pathology in the trachea as wild-type Rlow strains, and 
therefore, may display a different vlhA profile over the initial stages of infection. Preliminary 
data suggest that the in vivo vlhA expression profile of the live attenuated vaccine strains 
Mg7 and GT5 is different than that of wild-type Rlow, with the expression of vlhA 3.03 
continually increasing over the first two days of infection. This could be due to the fact that 
the vaccine strains do not cause significant damage to the tracheal mucosa as severe as Rlow, 
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therefore the environment is not changing significantly, and the M. gallisepticum is not 
stimulated to change predominant expression from vlhA 3.03.       
  Understanding these changes in vlhA expression and the effects those genes have on 
the virulence and persistence of the pathogen will be important in elucidating mechanisms of 
colonization, persistence,  and overall pathogenesis of M. gallisepticum in the natural host 
and  will provide information likely to be critical for development of rationally designed M. 
gallisepticum therapeutics and vaccines.  
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